Mequon, Wisconsin-based Titan Spine, Inc. has announced the closure of a “substantial round” of Series B financing with its investment partner, Southlake Equity Group. According to Titan, the company will use the proceeds to drive the next stage of growth of the company through product line additions, sales team expansion, and accelerated research and development.
Titan Spine Closes on Series B Funding
1 min read Premium comments
Secondary#nanolock#titanspine#southlakeequitygroup
The company stated, “Titan Spine and Southlake Equity Group first partnered in June 2016, when Titan closed its Series A round with Southlake Equity anchoring the investment. Since closing its Series A round, Titan has grown by nearly 65% in a North American spine market that grows in the low single digits annually…During the past two years, the company has also accelerated the transition from its line of Endoskeleton interbody devices that incorporate its original surface technology to those that feature its pioneering nanoLOCK surface technology. nanoLOCK is the only nanotechnology cleared by the FDA for orthopedic applications.”
Chief Executive Officer and President Peter Ullrich, M.D. commented: “Titan Spine’s core business is to help patients that are suffering from back pain enjoy healthier, productive and pain-free lives as quickly as possible following surgery.”
“Our nanoLOCK proprietary surface technology was designed to do just that by fueling the patient’s own healing mechanisms at the nano-level. The Series B round of financing will enable Titan Spine to help more patients with more products more quickly. We appreciate the continued support of Southlake Equity Group and are truly excited with the level of management investment in the Series B round.”
Southlake Equity Group Managing Partner Tom Keene added: “The management team of Titan is incredibly passionate about making patients’ lives better. It comes through loud and clear in every interaction with the great people of Titan at every level of the company.”
“We are pleased to lead the Series B round of financing and are very excited about working with the company as it continues to expand its ability to reach more patients. Titan Spine has grown at double digit rates for 12 years and has enormous potential in changing the landscape of surface technology-enhanced orthopedic products.”
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.